DK1296715T4 - Multivalent vaccinesammensætning. - Google Patents

Multivalent vaccinesammensætning. Download PDF

Info

Publication number: DK1296715T4
Authority: DK; Denmark
Prior art keywords: capsular polysaccharide; pneumoniae serotype; polysaccharide; immunogenic composition; oligosaccharides
Prior art date: 2000-06-29

Application number

DK01960390.1T

Other languages

English (en)

Other versions

DK1296715T3 (da

Inventor

Dominique Boutriau

Carine Capiau

Pierre Michel Desmons

Dominique Lemoine

Jan Poolman

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-29

Filing date

2001-06-27

Publication date

2016-03-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1296715(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-29 Priority claimed from GBGB0015999.6A external-priority patent/GB0015999D0/en

2001-04-03 Priority claimed from GBGB0108364.1A external-priority patent/GB0108364D0/en

2001-04-03 Priority claimed from GB0108363A external-priority patent/GB0108363D0/en

2001-06-27 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

2012-02-13 Application granted granted Critical

2012-02-13 Publication of DK1296715T3 publication Critical patent/DK1296715T3/da

2016-03-07 Publication of DK1296715T4 publication Critical patent/DK1296715T4/da

Links

239000000203 mixture Substances 0.000 title claims description 71
229940031348 multivalent vaccine Drugs 0.000 title 1
229920001282 polysaccharide Polymers 0.000 claims description 147
239000005017 polysaccharide Substances 0.000 claims description 147
150000004676 glycans Chemical class 0.000 claims description 145
230000002163 immunogen Effects 0.000 claims description 30
241000606768 Haemophilus influenzae Species 0.000 claims description 26
229920001542 oligosaccharide Polymers 0.000 claims description 25
230000001580 bacterial effect Effects 0.000 claims description 23
229960000814 tetanus toxoid Drugs 0.000 claims description 22
241000588650 Neisseria meningitidis Species 0.000 claims description 21
150000002482 oligosaccharides Chemical class 0.000 claims description 21
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 19
101710188053 Protein D Proteins 0.000 claims description 19
101710132893 Resolvase Proteins 0.000 claims description 19
102000014914 Carrier Proteins Human genes 0.000 claims description 17
108010078791 Carrier Proteins Proteins 0.000 claims description 17
238000000034 method Methods 0.000 claims description 16
239000002671 adjuvant Substances 0.000 claims description 13
229960003983 diphtheria toxoid Drugs 0.000 claims description 12
241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 10
208000015181 infectious disease Diseases 0.000 claims description 10
108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 7
230000004224 protection Effects 0.000 claims description 7
229940047650 haemophilus influenzae Drugs 0.000 claims description 6
241000947238 Neisseria meningitidis serogroup C Species 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
241000894006 Bacteria Species 0.000 claims description 4
241000191967 Staphylococcus aureus Species 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
241000921898 Neisseria meningitidis serogroup A Species 0.000 claims description 3
241001573069 Neisseria meningitidis serogroup Y Species 0.000 claims description 3
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
230000006806 disease prevention Effects 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 claims description 2
241000588655 Moraxella catarrhalis Species 0.000 claims description 2
101710183389 Pneumolysin Proteins 0.000 claims description 2
241000193998 Streptococcus pneumoniae Species 0.000 claims 1
229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
229960005486 vaccine Drugs 0.000 description 53
102000036639 antigens Human genes 0.000 description 25
108091007433 antigens Proteins 0.000 description 25
239000000427 antigen Substances 0.000 description 24
238000009472 formulation Methods 0.000 description 15
238000012360 testing method Methods 0.000 description 11
241000588832 Bordetella pertussis Species 0.000 description 10
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 9
229910052782 aluminium Inorganic materials 0.000 description 9
239000004411 aluminium Substances 0.000 description 9
239000002158 endotoxin Substances 0.000 description 9
150000003839 salts Chemical class 0.000 description 8
238000002649 immunization Methods 0.000 description 7
230000000844 anti-bacterial effect Effects 0.000 description 6
238000000746 purification Methods 0.000 description 6
201000005702 Pertussis Diseases 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
230000028993 immune response Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000003053 toxin Substances 0.000 description 5
231100000765 toxin Toxicity 0.000 description 5
241000193449 Clostridium tetani Species 0.000 description 4
241000186227 Corynebacterium diphtheriae Species 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000002965 ELISA Methods 0.000 description 3
241000700721 Hepatitis B virus Species 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
206010043376 Tetanus Diseases 0.000 description 3
238000001784 detoxification Methods 0.000 description 3
230000001627 detrimental effect Effects 0.000 description 3
206010013023 diphtheria Diseases 0.000 description 3
208000002672 hepatitis B Diseases 0.000 description 3
230000002480 immunoprotective effect Effects 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
108010021711 pertactin Proteins 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 2
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
229940001007 aluminium phosphate Drugs 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229940001442 combination vaccine Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000012634 fragment Substances 0.000 description 2
229940045808 haemophilus influenzae type b Drugs 0.000 description 2
229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 2
230000036039 immunity Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000004044 response Effects 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
-1 1-cyano-dimethylaminopyridinium tetrafluoroborate Chemical compound 0.000 description 1
108010060123 Conjugate Vaccines Proteins 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
230000002411 adverse Effects 0.000 description 1
159000000013 aluminium salts Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940031670 conjugate vaccine Drugs 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229940014135 meningitis vaccine Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229960001539 poliomyelitis vaccine Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

DK01960390.1T 2000-06-29 2001-06-27 Multivalent vaccinesammensætning. DK1296715T4 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB0015999.6A GB0015999D0 (en)	2000-06-29	2000-06-29	Novel compounds
GBGB0108364.1A GB0108364D0 (en)	2001-04-03	2001-04-03	Vaccine composition
GB0108363A GB0108363D0 (en)	2001-04-03	2001-04-03	Vaccine composition
PCT/EP2001/007288 WO2002000249A2 (en)	2000-06-29	2001-06-27	Multivalent vaccine composition

Publications (2)

Publication Number	Publication Date
DK1296715T3 DK1296715T3 (da)	2012-02-13
DK1296715T4 true DK1296715T4 (da)	2016-03-07

Family

ID=27255788

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK07116669.8T DK1946769T3 (da)	2000-06-29	2001-06-27	Multivalent vaccinesammensætning med nedsat dosis af Haemophilus influenzae type B
DK01960390.1T DK1296715T4 (da)	2000-06-29	2001-06-27	Multivalent vaccinesammensætning.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK07116669.8T DK1946769T3 (da)	2000-06-29	2001-06-27	Multivalent vaccinesammensætning med nedsat dosis af Haemophilus influenzae type B

Country Status (34)

Country	Link
US (2)	US20030180316A1 (da)
EP (4)	EP2279748A1 (da)
JP (2)	JP4870895B2 (da)
KR (3)	KR100898845B1 (da)
CN (2)	CN1449293B (da)
AP (1)	AP1695A (da)
AT (1)	ATE534402T1 (da)
AU (2)	AU2001281895C1 (da)
BG (2)	BG66238B1 (da)
BR (2)	BRPI0112057B8 (da)
CA (2)	CA2412497C (da)
CY (2)	CY1112280T1 (da)
CZ (1)	CZ20024224A3 (da)
DK (2)	DK1946769T3 (da)
DZ (1)	DZ3399A1 (da)
EA (2)	EA011480B1 (da)
EG (1)	EG24742A (da)
ES (2)	ES2385100T3 (da)
HU (3)	HU228384B1 (da)
IL (2)	IL153506A0 (da)
MA (1)	MA25824A1 (da)
MX (1)	MXPA03000198A (da)
MY (1)	MY133981A (da)
NO (1)	NO332495B1 (da)
NZ (1)	NZ523319A (da)
OA (1)	OA12302A (da)
PE (1)	PE20020126A1 (da)
PL (2)	PL393584A1 (da)
PT (2)	PT1946769E (da)
SI (2)	SI1946769T1 (da)
SK (1)	SK288007B6 (da)
UA (2)	UA85853C2 (da)
UY (1)	UY26801A1 (da)
WO (1)	WO2002000249A2 (da)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4540795B2 (ja) *	2000-03-10	2010-09-08	一般財団法人阪大微生物病研究会	生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン
GB0108364D0 (en) *	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
MY133981A (en)	2000-06-29	2007-11-30	Smithkline Beecham Biologicals S A	Vaccine composition
CA2435681C (en)	2001-01-23	2011-06-21	Aventis Pasteur	Multivalent meningococcal polysaccharide-protein conjugate vaccine
AU2007200116A1 (en) *	2001-04-03	2007-02-01	Glaxosmithkline Biologicals S.A.	Vaccine composition
EP2305299B1 (en)	2001-05-31	2017-03-01	GlaxoSmithKline Biologicals SA	Chimeric alphavirus replicon particles
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
DE60328481D1 (de)	2002-05-14	2009-09-03	Novartis Vaccines & Diagnostic	Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
BR0310042A (pt) *	2002-05-14	2005-04-05	Chiron Srl	Vacinas de combinação mucosal para meningite bacteriana
GB0302218D0 (en)	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
SI2353608T1 (sl)	2002-10-11	2020-12-31	Glaxosmithkline Biologicals Sa	Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
CA2503871C (en) *	2002-11-01	2012-12-11	Glaxosmithkline Biologicals S.A.	An immunogenic composition for generating an immune response against polio virus
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
JP2006516609A (ja) *	2003-01-30	2006-07-06	カイロンソチエタアレスポンサビリタリミタータ	粘膜髄膜炎菌性ワクチン
CN102302776B (zh) *	2003-01-30	2014-06-18	诺华疫苗和诊断有限公司	抗多种脑膜炎球菌血清组的可注射性疫苗
US20050002948A1 (en)	2003-05-07	2005-01-06	Ryall Robert P.	Method of enhanced immunogenicity to meningococcal vaccination
GB0313916D0 (en) *	2003-06-16	2003-07-23	Glaxosmithkline Biolog Sa	Vaccine composition
CA2530434A1 (en) *	2003-06-23	2005-01-06	Aventis Pasteur, Inc.	Immunization method against neisseria meningitidis serogroups a and c
PT1961426E (pt) *	2003-10-02	2011-06-28	Novartis Vaccines & Diagnostic	Vacinas combinadas contra a meningite
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
CU23404A1 (es) *	2003-11-19	2009-08-04	Ct Ingenieria Genetica Biotech	Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
GB0405787D0 (en) *	2004-03-15	2004-04-21	Chiron Srl	Low dose vaccines
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
EP1740217B1 (en)	2004-04-30	2011-06-15	Novartis Vaccines and Diagnostics S.r.l.	Meningococcal conjugate vaccination
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0502096D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Purification of streptococcal capsular polysaccharide
GB0505518D0 (en) *	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
US20070184072A1 (en) *	2005-04-08	2007-08-09	Wyeth	Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) *	2005-04-08	2011-06-07	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) *	2005-04-08	2010-05-04	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102611449B1 (ko)	2005-04-08	2023-12-06	와이어쓰 엘엘씨	다가 폐렴구균 다당류-단백질 접합체 조성물
EP2329843A3 (en)	2005-04-18	2011-09-14	Novartis Vaccines and Diagnostics, Inc.	Expressing Hepatitis B Virus surface antigen for vaccine preparation
GB0513069D0 (en) *	2005-06-27	2005-08-03	Glaxosmithkline Biolog Sa	Immunogenic composition
ES2662651T3 (es)	2005-06-27	2018-04-09	Glaxosmithkline Biologicals S.A.	Composición inmunógena
CN1709505B (zh) *	2005-07-13	2010-06-16	北京绿竹生物制药有限公司	多价细菌荚膜多糖-蛋白质结合物联合疫苗
EP2308504A3 (en) *	2005-09-01	2011-11-30	Novartis Vaccines and Diagnostics GmbH	Multiple vaccines including serogroup C meningococcus
EP1945247A1 (en)	2005-10-18	2008-07-23	Novartis Vaccines and Diagnostics, Inc.	Mucosal and systemic immunizations with alphavirus replicon particles
GB0522765D0 (en)	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
SI1962899T1 (sl) *	2005-12-22	2011-11-30	Glaxosmithkline Biolog Sa	Pnevmokokna polisaharidna konjugatna vakcina
GB0607088D0 (en) *	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
JP2009520771A (ja) *	2005-12-23	2009-05-28	グラクソスミスクラインバイオロジカルズソシエテアノニム	コンジュゲートワクチン
EA015561B1 (ru) *	2006-01-17	2011-08-30	Арне Форсгрен	НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE)
SI2004225T1 (sl)	2006-03-22	2012-08-31	Novartis Ag	Reĺ˝imi za imunizacijo z meningokoknimi konjugati
TW200806315A (en) *	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en)	2006-05-08	2014-08-19	Wyeth Llc	Pneumococcal dosing regimen
EP1872791A1 (en)	2006-06-30	2008-01-02	Institut Pasteur	Use of bacterial polysaccharides for biofilm inhibition
EA015964B1 (ru) *	2006-09-07	2012-01-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
EP2682127A1 (en)	2007-05-02	2014-01-08	GlaxoSmithKline Biologicals S.A.	Vaccine
JP5637848B2 (ja)	2007-06-04	2014-12-10	ノバルティスアーゲー	髄膜炎ワクチンの製剤化
ES2626662T3 (es)	2007-06-26	2017-07-25	Glaxosmithkline Biologicals S.A.	Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
RU2477145C2 (ru) *	2008-05-30	2013-03-10	ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ	Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
PE20100365A1 (es) *	2008-10-24	2010-05-21	Panacea Biotec Ltd	Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
TW201136603A (en) *	2010-02-09	2011-11-01	Merck Sharp & Amp Dohme Corp	15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
ES2614807T3 (es) *	2010-06-04	2017-06-02	Wyeth Llc	Formulaciones vacunales
UA110118C2 (uk) *	2010-12-14	2015-11-25	Ґлаксосмітклайн Байолоджікалз С.А.	Мікобактеріальна антигенна композиція
US10092640B2 (en)	2011-01-05	2018-10-09	Bharat Biotech International Limited	Combination heptavalent vaccine
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
DE102011118371B4 (de)	2011-11-11	2014-02-13	Novartis Ag	Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de)	2011-11-11	2014-12-24	Novartis Ag	Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en)	2011-11-11	2013-05-15	Novartis AG	Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en)	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products
ES2707294T3 (es) *	2012-01-30	2019-04-03	Serum Institute Of India Pvt Ltd	Composición inmunogénica
JP2015509963A (ja) *	2012-03-08	2015-04-02	ノバルティスアーゲー	Ｔｌｒ４アゴニストを含む混合ワクチン
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
CA2879939A1 (en)	2012-08-06	2014-02-13	Glaxosmithkline Biologicals S.A.	Novel method
SG11201502599TA (en)	2012-10-12	2015-05-28	Glaxosmithkline Biolog Sa	Non-cross-linked acellular pertussis antigens for use in combination vaccines
BR112015008418A2 (pt) *	2012-10-17	2017-07-04	Glaxosmithkline Biologicals Sa	uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae
KR20140075201A (ko) *	2012-12-11	2014-06-19	에스케이케미칼주식회사	다가 폐렴구균 다당류-단백질 접합체 조성물
CN105007936B (zh)	2013-03-08	2018-10-02	扬森疫苗与预防公司	无细胞百日咳疫苗
MX2016000099A (es) *	2013-07-07	2016-07-07	Max Planck Ges Zur Förderung Der Wissenschaften E V	Vacunas sinteticas contra streptococcus pneumoniae tipo 1.
CA2919773A1 (en)	2013-08-05	2015-02-12	Glaxosmithkline Biologicals S.A.	Combination immunogenic compositions
US11160855B2 (en) *	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9815886B2 (en)	2014-10-28	2017-11-14	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
RU2626532C2 (ru) *	2015-01-16	2017-07-28	Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации	Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
KR20190049940A (ko) *	2015-02-19	2019-05-09	화이자 인코포레이티드	나이세리아 메닌지티디스 조성물 및 그의 방법
CA3031799A1 (en)	2016-08-05	2018-02-08	Sanofi Pasteur, Inc.	Multivalent pneumococcal polysaccharide-protein conjugate composition
PH12019500238B1 (en)	2016-08-05	2023-05-10	Sanofi Pasteur Inc	Multivalent pneumococcal polysaccharide-protein conjugate composition
HRP20240433T1 (hr)	2016-09-02	2024-07-05	Sanofi Pasteur, Inc.	Cjepivo protiv neisseria meningitidis
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AR114154A1 (es)	2017-12-06	2020-07-29	Merck Sharp & Dohme	Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos
KR102486891B1 (ko)	2018-02-05	2023-01-10	사노피 파스퇴르 인코포레이티드	다가 폐렴구균성 다당류-단백질 접합체 조성물
WO2019152921A1 (en)	2018-02-05	2019-08-08	Sanofi Pasteur Inc.	Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019256218A1 (en)	2018-04-18	2020-12-03	Sk Bioscience Co., Ltd.	Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
CN112041435B (zh) *	2018-04-30	2024-05-31	默沙东有限责任公司	提供冻干的突变白喉毒素在二甲基亚砜中的均质溶液的方法
KR20200005458A (ko)	2018-07-06	2020-01-15	주식회사 유바이오로직스	다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
US20210401960A1 (en) *	2018-11-10	2021-12-30	Bharat Biotech International Limited	Multivalent glycoconjugates immunogenic compositions
KR20240169145A (ko)	2018-12-19	2024-12-02	머크 샤프 앤드 돔 엘엘씨	스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
CA3141460A1 (en)	2019-05-20	2020-11-26	Soligenix, Inc.	Compositions and methods of manufacturing trivalent filovirus vaccines
CN111821432B (zh) *	2020-08-05	2022-10-18	北京智飞绿竹生物制药有限公司	一种多价肺炎球菌结合疫苗
WO2025109417A1 (en) *	2023-11-21	2025-05-30	Panacea Biotec Limited	Immunogenic composition of haemophilus influenzae conjugated to protein d

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4057685A (en) *	1972-02-02	1977-11-08	Abbott Laboratories	Chemically modified endotoxin immunizing agent
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) *	1979-09-21	1986-05-22	Hitachi Ltd	Semiconductor switch
US4372945A (en)	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en)	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) *	1981-08-31	1987-06-16	Anderson Porter W	Immunogenic conjugates
US4459286A (en) *	1983-01-31	1984-07-10	Merck & Co., Inc.	Coupled H. influenzae type B vaccine
JPS6061288A (ja) *	1983-09-13	1985-04-09	Fuji Photo Film Co Ltd	感熱記録材料
US4808700A (en) *	1984-07-09	1989-02-28	Praxis Biologics, Inc.	Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) *	1985-06-07	1987-11-24	President And Fellows Of Harvard College	Modified toxic vaccines
GB8516442D0 (en)	1985-06-28	1985-07-31	Wellcome Found	Cloned antigen
GB8727489D0 (en)	1987-11-24	1987-12-23	Connaught Lab	Detoxification of pertussis toxin
GB8914122D0 (en)	1989-06-20	1989-08-09	Wellcome Found	Polypeptide expression
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2059692C (en) *	1991-01-28	2004-11-16	Peter J. Kniskern	Pneumoccoccal polysaccharide conjugate vaccine
ES2130265T3 (es)	1992-05-06	1999-07-01	Harvard College	Region de union al receptor de la toxina difterica.
ES2118963T3 (es) *	1992-05-23	1998-10-01	Smithkline Beecham Biolog	Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
DE69327534T2 (de)	1992-06-18	2000-06-08	The President And Fellows Of Harvard College, Cambridge	Impfstoffe gegen diphtherietoxin
PT761231E (pt)	1992-06-25	2000-06-30	Smithkline Beecham Biolog	Composicao de vacina contendo adjuvantes
DE69323264T4 (de) *	1992-10-27	1999-10-14	American Cyanamid Co.	Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
AU678613B2 (en) *	1993-09-22	1997-06-05	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5849301A (en) *	1993-09-22	1998-12-15	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5869058A (en) *	1994-05-25	1999-02-09	Yeda Research And Development Co. Ltd.	Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5917017A (en)	1994-06-08	1999-06-29	President And Fellows Of Harvard College	Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) *	1994-06-08	2002-09-24	President And Fellows Of Harvard College	Multi-mutant diphtheria toxin vaccines
CA2560114A1 (en)	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
GB9422096D0 (en) *	1994-11-02	1994-12-21	Biocine Spa	Combined meningitis vaccine
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ES2157447T5 (es) *	1995-06-23	2011-04-29	Smithkline Beecham Biologicals S.A.	Una composición de vacuna que comprende un antígeno conjugado de polisacárido de haemofilus influenzae tipo b adsorbido en fosfato de aluminio.
US5997881A (en)	1995-11-22	1999-12-07	University Of Maryland, Baltimore	Method of making non-pyrogenic lipopolysaccharide or A
WO1998033923A1 (en)	1997-01-30	1998-08-06	Imperial College Of Science, Technology & Medicine	MUTANT msbB or htrB GENES
PT1028750E (pt) *	1997-09-15	2006-05-31	Sanofi Pasteur Msd	Metodo de preparacao de vacinas polivalentes
US5965714A (en) *	1997-10-02	1999-10-12	Connaught Laboratories, Inc.	Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en)	1998-02-23	2006-03-28	Aventis Pasteur, Inc	Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
US6146902A (en) *	1998-12-29	2000-11-14	Aventis Pasteur, Inc.	Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB9925559D0 (en) *	1999-10-28	1999-12-29	Smithkline Beecham Biolog	Novel method
FR2806304B1 (fr) *	2000-03-17	2002-05-10	Aventis Pasteur	Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0108364D0 (en) *	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
MY133981A (en)	2000-06-29	2007-11-30	Smithkline Beecham Biologicals S A	Vaccine composition
AU2003257003A1 (en) *	2002-07-30	2004-02-16	Baxter Healthcare S.A.	Chimeric multivalent polysaccharide conjugate vaccines
GB0405787D0 (en) *	2004-03-15	2004-04-21	Chiron Srl	Low dose vaccines
GB0500787D0 (en) *	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0428394D0 (en) *	2004-12-24	2005-02-02	Chiron Srl	Saccharide conjugate vaccines
GB0502095D0 (en) *	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
ES2662651T3 (es) *	2005-06-27	2018-04-09	Glaxosmithkline Biologicals S.A.	Composición inmunógena
SI1962899T1 (sl) *	2005-12-22	2011-11-30	Glaxosmithkline Biolog Sa	Pnevmokokna polisaharidna konjugatna vakcina
GB0607088D0 (en) *	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
JP2009520771A (ja) *	2005-12-23	2009-05-28	グラクソスミスクラインバイオロジカルズソシエテアノニム	コンジュゲートワクチン
GB0700136D0 (en) *	2007-01-04	2007-02-14	Glaxosmithkline Biolog Sa	Process for manufacturing vaccines
GB0700135D0 (en) *	2007-01-04	2007-02-14	Glaxosmithkline Biolog Sa	Vaccine
US8885224B2 (en) *	2007-03-14	2014-11-11	Konica Minolta Business Technologies, Inc.	Information embedding method, its program and information embedding device
EP2682127A1 (en) *	2007-05-02	2014-01-08	GlaxoSmithKline Biologicals S.A.	Vaccine
JP5637848B2 (ja) *	2007-06-04	2014-12-10	ノバルティスアーゲー	髄膜炎ワクチンの製剤化
ES2626662T3 (es) *	2007-06-26	2017-07-25	Glaxosmithkline Biologicals S.A.	Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae

2001
- 2001-06-27 MY MYPI20013027 patent/MY133981A/en unknown
- 2001-06-27 SK SK1843-2002A patent/SK288007B6/sk not_active IP Right Cessation
- 2001-06-27 AT AT01960390T patent/ATE534402T1/de active
- 2001-06-27 DK DK07116669.8T patent/DK1946769T3/da active
- 2001-06-27 HU HU0301413A patent/HU228384B1/hu unknown
- 2001-06-27 EG EG20010701A patent/EG24742A/xx active
- 2001-06-27 KR KR1020087013186A patent/KR100898845B1/ko not_active Expired - Lifetime
- 2001-06-27 CN CN018146198A patent/CN1449293B/zh not_active Expired - Lifetime
- 2001-06-27 IL IL15350601A patent/IL153506A0/xx unknown
- 2001-06-27 KR KR1020027017928A patent/KR100837917B1/ko not_active Expired - Lifetime
- 2001-06-27 SI SI200131012T patent/SI1946769T1/sl unknown
- 2001-06-27 JP JP2002505030A patent/JP4870895B2/ja not_active Expired - Lifetime
- 2001-06-27 PT PT07116669T patent/PT1946769E/pt unknown
- 2001-06-27 AU AU2001281895A patent/AU2001281895C1/en active Active
- 2001-06-27 PE PE2001000629A patent/PE20020126A1/es not_active Application Discontinuation
- 2001-06-27 EA EA200501070A patent/EA011480B1/ru not_active IP Right Cessation
- 2001-06-27 BR BRPI0112057A patent/BRPI0112057B8/pt not_active IP Right Cessation
- 2001-06-27 PL PL393584A patent/PL393584A1/pl unknown
- 2001-06-27 UA UAA200604994A patent/UA85853C2/uk unknown
- 2001-06-27 WO PCT/EP2001/007288 patent/WO2002000249A2/en active IP Right Grant
- 2001-06-27 EP EP10178449A patent/EP2279748A1/en not_active Withdrawn
- 2001-06-27 BR BR122012003821A patent/BR122012003821B8/pt not_active IP Right Cessation
- 2001-06-27 SI SI200131007T patent/SI1296715T2/sl unknown
- 2001-06-27 CA CA2412497A patent/CA2412497C/en not_active Expired - Lifetime
- 2001-06-27 US US10/312,090 patent/US20030180316A1/en not_active Abandoned
- 2001-06-27 EP EP10178451A patent/EP2277541A1/en not_active Withdrawn
- 2001-06-27 DK DK01960390.1T patent/DK1296715T4/da active
- 2001-06-27 ES ES07116669T patent/ES2385100T3/es not_active Expired - Lifetime
- 2001-06-27 EP EP01960390.1A patent/EP1296715B2/en not_active Expired - Lifetime
- 2001-06-27 AP APAP/P/2002/002700A patent/AP1695A/en active
- 2001-06-27 UY UY26801A patent/UY26801A1/es not_active IP Right Cessation
- 2001-06-27 AU AU8189501A patent/AU8189501A/xx active Pending
- 2001-06-27 PL PL360265A patent/PL210015B1/pl unknown
- 2001-06-27 MX MXPA03000198A patent/MXPA03000198A/es active IP Right Grant
- 2001-06-27 EP EP07116669A patent/EP1946769B1/en not_active Expired - Lifetime
- 2001-06-27 OA OA1200200395A patent/OA12302A/en unknown
- 2001-06-27 DZ DZ013399A patent/DZ3399A1/xx active
- 2001-06-27 CN CN200910174266.7A patent/CN101708333B/zh not_active Expired - Lifetime
- 2001-06-27 KR KR1020077019832A patent/KR20070091698A/ko not_active Ceased
- 2001-06-27 HU HU1000594A patent/HU227613B1/hu unknown
- 2001-06-27 CA CA2783274A patent/CA2783274C/en not_active Expired - Lifetime
- 2001-06-27 PT PT01960390T patent/PT1296715E/pt unknown
- 2001-06-27 HU HU1000593A patent/HU227893B1/hu unknown
- 2001-06-27 CZ CZ20024224A patent/CZ20024224A3/cs not_active IP Right Cessation
- 2001-06-27 ES ES01960390.1T patent/ES2375704T5/es not_active Expired - Lifetime
- 2001-06-27 NZ NZ523319A patent/NZ523319A/en not_active IP Right Cessation
- 2001-06-27 UA UA20021210397A patent/UA76952C2/uk unknown
- 2001-06-27 EA EA200201240A patent/EA006313B1/ru not_active IP Right Cessation
2002
- 2002-12-17 IL IL153506A patent/IL153506A/en active IP Right Grant
- 2002-12-20 NO NO20026175A patent/NO332495B1/no not_active IP Right Cessation
- 2002-12-26 MA MA26980A patent/MA25824A1/fr unknown
- 2002-12-28 BG BG107422A patent/BG66238B1/bg active Active
2009
- 2009-11-06 BG BG10110518A patent/BG66249B1/bg active Active
2010
- 2010-03-15 JP JP2010057779A patent/JP5346308B2/ja not_active Expired - Lifetime
2012
- 2012-01-30 CY CY20121100103T patent/CY1112280T1/el unknown
- 2012-04-04 US US13/439,829 patent/US9233151B2/en not_active Expired - Fee Related
- 2012-06-15 CY CY20121100549T patent/CY1112915T1/el unknown

Also Published As

Publication number	Publication date
PL210015B1 (pl)	2011-11-30
CA2783274A1 (en)	2002-01-03
NO20026175L (no)	2003-02-26
ES2375704T5 (es)	2016-03-03
EP1946769B1 (en)	2012-05-30
EP1296715A2 (en)	2003-04-02
AU8189501A (en)	2002-01-08
HK1055244A1 (en)	2004-01-02
EP1296715B1 (en)	2011-11-23
CA2783274C (en)	2018-08-07
CN1449293B (zh)	2012-08-22
MY133981A (en)	2007-11-30
PT1946769E (pt)	2012-06-27
BG107422A (bg)	2003-09-30
DK1946769T3 (da)	2012-07-16
EA200201240A1 (ru)	2003-06-26
BR0112057A (pt)	2003-06-17
BG66249B1 (en)	2012-09-28
HU228384B1 (en)	2013-03-28
PL393584A1 (pl)	2011-05-23
ES2385100T3 (es)	2012-07-18
IL153506A0 (en)	2003-07-06
EA200501070A1 (ru)	2006-02-24
SK288007B6 (sk)	2012-10-02
UA76952C2 (uk)	2006-10-16
AU2001281895B2 (en)	2005-04-28
ES2375704T3 (es)	2012-03-05
JP5346308B2 (ja)	2013-11-20
HU1000593D0 (en)	2010-12-28
SI1296715T1 (sl)	2012-03-30
KR100837917B1 (ko)	2008-06-13
EP2277541A1 (en)	2011-01-26
US9233151B2 (en)	2016-01-12
NZ523319A (en)	2006-01-27
EP1296715B2 (en)	2015-12-23
WO2002000249A2 (en)	2002-01-03
BG66238B1 (bg)	2012-08-31
IL153506A (en)	2009-06-15
SI1296715T2 (sl)	2016-03-31
PE20020126A1 (es)	2002-04-27
HU227613B1 (en)	2011-09-28
BR122012003821B1 (pt)	2020-09-01
KR20080052700A (ko)	2008-06-11
MXPA03000198A (es)	2004-09-13
ATE534402T1 (de)	2011-12-15
CY1112280T1 (el)	2015-12-09
HU227893B1 (en)	2012-05-29
CN101708333B (zh)	2014-03-26
PL360265A1 (en)	2004-09-06
CA2412497C (en)	2012-10-02
BR122012003821B8 (pt)	2021-05-25
DK1296715T3 (da)	2012-02-13
BRPI0112057B8 (pt)	2021-05-25
KR20070091698A (ko)	2007-09-11
EP1946769A2 (en)	2008-07-23
AU2001281895C1 (en)	2005-10-27
CY1112915T1 (el)	2016-04-13
AP2002002700A0 (en)	2002-12-31
EG24742A (en)	2010-07-14
DZ3399A1 (fr)	2002-01-03
UA85853C2 (uk)	2009-03-10
US20030180316A1 (en)	2003-09-25
JP2004501873A (ja)	2004-01-22
BG110518A (bg)	2010-04-30
CA2412497A1 (en)	2002-01-03
CZ20024224A3 (cs)	2003-05-14
CN1449293A (zh)	2003-10-15
JP4870895B2 (ja)	2012-02-08
US20120207780A1 (en)	2012-08-16
MA25824A1 (fr)	2003-07-01
NO20026175D0 (no)	2002-12-20
EA011480B1 (ru)	2009-04-28
WO2002000249A3 (en)	2002-06-13
SK18432002A3 (sk)	2003-08-05
SI1946769T1 (sl)	2012-07-31
JP2010163453A (ja)	2010-07-29
KR20030024714A (ko)	2003-03-26
CN101708333A (zh)	2010-05-19
OA12302A (en)	2003-10-24
NO332495B1 (no)	2012-10-01
UY26801A1 (es)	2002-01-31
BRPI0112057B1 (pt)	2016-10-04
AP1695A (en)	2006-12-17
PT1296715E (pt)	2012-01-19
EP2279748A1 (en)	2011-02-02
EP1946769A3 (en)	2008-07-30
EA006313B1 (ru)	2005-10-27
KR100898845B1 (ko)	2009-05-21
HUP0301413A3 (en)	2010-01-28
HU1000594D0 (en)	2010-12-28
HUP0301413A1 (hu)	2003-08-28

Publication	Publication Date	Title
DK1296715T4 (da)	2016-03-07	Multivalent vaccinesammensætning.
EP1946771B1 (en)	2012-06-27	Multivalent vaccine composition
AU2001281895A1 (en)	2002-03-28	Vaccine Composition
HK1055244B (en)	2012-04-27	Multivalent vaccine composition
HK1055244C (en)	2012-04-27	Multivalent vaccine composition
ZA200300755B (en)	2004-04-28	Multivalent vaccine composition.
HK1114781B (en)	2012-11-16	Multivalent vaccine composition
HK1114782A (en)	2008-11-14	Multivalent vaccine composition with reduced dose of haemophilus influenzae type b
AU2002310903A1 (en)	2002-10-21	Vaccine composition
HK1149900A (en)	2011-10-21	Vaccine composition
AU2005203302A1 (en)	2005-08-18	Vaccine composition
HK1114779B (en)	2012-09-28	Multivalent vaccine composition
HK1062891B (en)	2012-09-28	Vaccine composition